Fierce Healthcare June 22, 2021
Weill Cornell Medical has launched a $1.5 billion campaign to invest in bench-to-bedside research, including precision health, genomics and artificial intelligence.
The New York-based institution has already raised more than $750 million from existing benefactors.
“The COVID-19 pandemic has demonstrated just how important medicine is to protect and enhance the health of our patients,” said Augustine M.K. Choi, M.D., the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine and provost for medical affairs of Cornell University in a statement.
“Our accomplished physicians and scientists are committed to treating the whole patient for their whole lifespan, applying cutting-edge science and a personalized and evidence-based approach to prevent and treat disease. Because of our generous donors, Weill Cornell Medicine is uniquely...
Today's Sponsors
Today's Sponsor